Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Cytarabine × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 392 Lymphoid 220 Myeloid 70 Classical hematology 25 Sarcoma 15 Plasma cell 10 CNS 5 Dermatologic 2 Other 1 Genitourinary 1 Breast 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 178 Prednisone 125 enzalutamide 107 Gemcitabine 101 Radiotherapy 100 Sunitinib 90 Leuprolide 83 pembrolizumab 82 Cisplatin 82 Abiraterone Acetate 79 Nivolumab 75 bicalutamide 69 Paclitaxel 69 Goserelin 68 Carboplatin 65 Sorafenib 63 Everolimus 61 Bevacizumab 53 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 50 Magnetic Resonance Spectroscopy 49 pazopanib 48 Ipilimumab 44 radium Ra 223 dichloride 39 Zoledronic Acid 39 Radiosurgery 38 Cyclophosphamide 37 Filgrastim 36 abiraterone 34 apalutamide 33 aldesleukin 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00480090 2019-02-15

SLAP

University Health Network, Toronto

Phase 2 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡